Widely used to induce memory or cognitive deficits in rodent models for dementia-related studies [79], scopolamine-driven neurodegeneration in rats is reported, including increased Aβ protein, APP mRNA levels, phosphorylated tau, and GSK-3β levels [80]. This evidence concerns the gene MAPT and Cognitive impairment.